Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. (THRX): 4 pipeline candidates · ~54 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
54.1 months
D/E 0.04 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Theseus Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$47.3M
Quarterly Burn
$11.0M
Runway
54.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| BCR-ABL TKI | Preclinical |
| Fourth-Generation EGFR Inhibitor | Preclinical |
| THE-349 | Preclinical |
| THE-630 | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in Theseus Pharmaceuticals, Inc.'s pipeline?
Theseus Pharmaceuticals, Inc. (THRX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Theseus Pharmaceuticals, Inc.'s lead drug candidate?
Theseus Pharmaceuticals, Inc.'s most advanced tracked candidate is BCR-ABL TKI (Preclinical) for Relapsed/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
What is Theseus Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Theseus Pharmaceuticals, Inc. has approximately 54.1 months of cash runway.
Who is the CEO of Theseus Pharmaceuticals, Inc.?
Chief Executive Officer is the chief executive officer of Theseus Pharmaceuticals, Inc. (THRX).
Get the full picture on Theseus Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.